Aytu Biopharma, Inc. (AYTU)
2.14
+0.02
(+0.94%)
USD |
NASDAQ |
Sep 21, 16:00
2.14
0.00 (0.00%)
After-Hours: 20:00
Aytu Biopharma Enterprise Value : 18.98M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 18.98M |
| September 17, 2026 | 17.69M |
| September 16, 2026 | 17.37M |
| September 15, 2026 | 17.58M |
| September 14, 2026 | 17.69M |
| September 11, 2026 | 17.58M |
| September 10, 2026 | 18.23M |
| September 09, 2026 | 18.98M |
| September 08, 2026 | 19.73M |
| September 04, 2026 | 19.94M |
| September 03, 2026 | 20.75M |
| September 02, 2026 | 20.69M |
| September 01, 2026 | 20.37M |
| August 31, 2026 | 20.80M |
| August 28, 2026 | 20.37M |
| August 27, 2026 | 20.27M |
| August 26, 2026 | 20.91M |
| August 25, 2026 | 21.45M |
| August 24, 2026 | 21.02M |
| August 21, 2026 | 21.66M |
| August 20, 2026 | 20.69M |
| August 19, 2026 | 21.55M |
| August 18, 2026 | 21.55M |
| August 17, 2026 | 21.55M |
| August 14, 2026 | 21.77M |
| Date | Value |
|---|---|
| August 13, 2026 | 20.91M |
| August 12, 2026 | 21.55M |
| August 11, 2026 | 21.99M |
| August 10, 2026 | 21.77M |
| August 07, 2026 | 21.55M |
| August 06, 2026 | 21.23M |
| August 05, 2026 | 20.91M |
| August 04, 2026 | 19.94M |
| August 03, 2026 | 20.37M |
| July 31, 2026 | 20.16M |
| July 30, 2026 | 19.30M |
| July 29, 2026 | 18.55M |
| July 28, 2026 | 19.08M |
| July 27, 2026 | 18.33M |
| July 24, 2026 | 19.41M |
| July 23, 2026 | 19.41M |
| July 22, 2026 | 19.41M |
| July 21, 2026 | 19.62M |
| July 20, 2026 | 19.41M |
| July 17, 2026 | 19.30M |
| July 16, 2026 | 19.41M |
| July 15, 2026 | 20.05M |
| July 14, 2026 | 19.84M |
| July 13, 2026 | 19.62M |
| July 10, 2026 | 20.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.984B |
| Corcept Therapeutics, Inc. | 11.60B |
| Veru, Inc. | 17.98M |
| Johnson & Johnson | 678.48B |
| Eli Lilly & Co. | 1.131T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.618M |
| Revenue (Quarterly) | 12.41M |
| Total Expenses (Quarterly) | 18.03M |
| EPS Diluted (Quarterly) | -0.5345 |
| Gross Profit Margin (Quarterly) | 55.10% |
| Profit Margin (Quarterly) | -45.27% |
| Earnings Yield | -214.2% |
| Normalized Earnings Yield | -174.43 |